DeepMed Research

CL AVIATION, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

Phase 1

Terminated

Conditions: ER-positive Breast Cancer
HER2-positive Breast Cancer

Interventions: Drug: fulvestrant 500 mg
Drug: Docetaxel
Drug: Trastuzumab (H, 8mg/kg
Drug: Pertuzumab (P, 840 mg

First Posted Date: 2015-01-26

Last Posted Date: 2018-02-20

Lead Sponsor: Western Regional Medical Center

Target Recruit Count: 4

Registration Number: NCT02345772

Locations: 🇺🇸
Western Regional Medical Center, Inc., Goodyear, Arizona, United States

Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis

Phase 2

Withdrawn

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Oxaliplatin
Drug: Folinic Acid
Drug: 5-Fluorouracil

First Posted Date: 2015-01-26

Last Posted Date: 2017-08-24

Lead Sponsor: Western Regional Medical Center

Registration Number: NCT02345746

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Phase 1

Terminated

Conditions: Pancreatic Cancer
Small Cell Lung Cancer
Ovarian
Sarcoma
Advanced Cancer
Breast Cancer

Interventions: Drug: Pembrolizumab
Drug: Gemcitabine
Drug: Liposomal Doxorubicin
Drug: Irinotecan
Drug: Docetaxel
Drug: Nab-paclitaxel
Drug: Vinorelbine

First Posted Date: 2015-01-06

Last Posted Date: 2018-07-02

Lead Sponsor: Western Regional Medical Center

Target Recruit Count: 81

Registration Number: NCT02331251

Locations: 🇺🇸
Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸
Western Regional Medical Center, Goodyear, Arizona, United States

Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer

Phase 1

Terminated

Conditions: Breast Cancer
Advanced Cancer
Colorectal Cancer
Gastric Cancer
Esophageal Cancer

Interventions: Drug: Pembrolizumab
Drug: ado-trastuzumab emtansine
Drug: Cetuximab
Drug: Trastuzumab

First Posted Date: 2014-12-17

Last Posted Date: 2019-10-21

Lead Sponsor: Western Regional Medical Center

Target Recruit Count: 16

Registration Number: NCT02318901

Locations: 🇺🇸
Western Regional Medical Center/Cancer Treatment Center of America, Goodyear, Arizona, United States

Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for Treatment

Not Applicable

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Genetic: Standard of care based on target(s) identified via GWS.

First Posted Date: 2014-11-21

Last Posted Date: 2017-11-09

Lead Sponsor: Western Regional Medical Center

Target Recruit Count: 12

Registration Number: NCT02297087

Locations: 🇺🇸
Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States

L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer

Phase 1

Withdrawn

Conditions: Peripheral Neuropathy

Interventions: Dietary Supplement: L-glutamine

First Posted Date: 2014-08-13

Last Posted Date: 2017-07-12

Lead Sponsor: Eastern Regional Medical Center

Registration Number: NCT02215083

Locations: 🇺🇸
Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States

Does Serum Procalcitonin Levels Predict Sepsis in Patients Undergoing Cytoreductive Surgery

Completed

Conditions: Cytoreductive Surgery

Interventions: Other: Serum procalcitonin lab draws

First Posted Date: 2014-07-14

Last Posted Date: 2017-07-12

Lead Sponsor: Eastern Regional Medical Center

Target Recruit Count: 20

Registration Number: NCT02189434

Locations: 🇺🇸
Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States

Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions

Phase 1

Conditions: Loculated or Non-draining Malignant Pleural Effusions

Interventions: Drug: Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)

First Posted Date: 2014-05-12

Last Posted Date: 2021-02-11

Lead Sponsor: Eastern Regional Medical Center

Target Recruit Count: 10

Registration Number: NCT02135588

Locations: 🇺🇸
Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States

Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: HAI with FOLFOX

First Posted Date: 2013-09-09

Last Posted Date: 2018-02-07

Lead Sponsor: Western Regional Medical Center

Target Recruit Count: 2

Registration Number: NCT01937507

Locations: 🇺🇸
Western Regional Medical Center Inc, Goodyear, Arizona, United States

(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma

Phase 2

Terminated

Conditions: Ovarian Carcinoma
Fallopian Tube Carcinoma
Peritoneal Carcinoma

Interventions: Drug: Gemcitabine
Drug: Bevacizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Oxaliplatin

First Posted Date: 2013-09-06

Last Posted Date: 2018-02-20

Lead Sponsor: Western Regional Medical Center

Target Recruit Count: 7

Registration Number: NCT01936974

Locations: 🇺🇸
Western Regional Medical Center, Goodyear, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy